Résumé
A prospective randomized study to evaluate the effect of intra-operative use of Albumin [20%] infusion prior to graft reperfusion on the severity of reperfusion syndrome during living donor liver transplantation Twenty patients were included with Child-Pughs C classification [ESLD]. Samples and measurements were taken pnor to reperfusion, during and after reperfusion of the donor liver graft. I. V fluids, blood and blood products were used to adjust a Hb level at [8-10 gm/dl] and Hct between 24-28% for better graft function and survival The reperfusion syndrome was severe as regard the decrease in MABP in No Albumin group [MABP = 48.2 +/- 7.23 mmHg] compared to Albumin group [MABP = 63.45 +/- 6.96 mmHg]. [P=00002] CVP was highly significant increased in Albumin group during reperfusion compared to No Albumin group [p = 0.0002]. Also. CVP correlated positively with S albumin level [r = 0.81. p = 0.002] dunng reperfusion syndrome. Patients of No Albumin group needed more motropic support than patients of Albumin group. In conclusion Albumin 20% in a dose of 1.5 ml/kg causes volume retention and expansion of intravascuiar volume which was a beneficial effect in liver transplant surgery to elevate the CVP prior to graft reperfusion and hence decreasing the severity of reperfusion syndrome and also elevating the already low serum albumin level and oncotic pressure